479 related articles for article (PubMed ID: 16932982)
1. Long terminal repeats are not the sole determinants of virulence for equine infectious anemia virus.
Tu YB; Zhou T; Yuan XF; Qiu HJ; Xue F; Sun CQ; Wang L; Wu DL; Peng JM; Kong XG; Tong GZ
Arch Virol; 2007 Jan; 152(1):209-18. PubMed ID: 16932982
[TBL] [Abstract][Full Text] [Related]
2. Long terminal repeat sequences from virulent and attenuated equine infectious anemia virus demonstrate distinct promoter activities.
Zhou T; Yuan XF; Hou SH; Tu YB; Peng JM; Wen JX; Qiu HJ; Wu DL; Chen HC; Wang XJ; Tong GZ
Virus Res; 2007 Sep; 128(1-2):58-64. PubMed ID: 17499380
[TBL] [Abstract][Full Text] [Related]
3. Genomic comparison between attenuated Chinese equine infectious anemia virus vaccine strains and their parental virulent strains.
Wang X; Wang S; Lin Y; Jiang C; Ma J; Zhao L; Lv X; Wang F; Shen R; Kong X; Zhou J
Arch Virol; 2011 Feb; 156(2):353-7. PubMed ID: 21136127
[TBL] [Abstract][Full Text] [Related]
4. Replication ability in vitro and in vivo of equine infectious anemia virus avirulent Japanese strain.
Zheng YH; Sentsui H; Sugita M; Nakaya T; Kishi M; Hagiwara K; Inoshima Y; Ishihara C; Kono Y; Lu JL; Ikuta K
Virology; 2000 Jan; 266(1):129-39. PubMed ID: 10612667
[TBL] [Abstract][Full Text] [Related]
5. Combined amino acid mutations occurring in the envelope closely correlate with pathogenicity of EIAV.
Liang H; He X; Shen RX; Shen T; Tong X; Ma Y; Xiang WH; Zhang XY; Shao YM
Arch Virol; 2006 Jul; 151(7):1387-403. PubMed ID: 16502285
[TBL] [Abstract][Full Text] [Related]
6. Effects of long terminal repeat sequence variation on equine infectious anemia virus replication in vitro and in vivo.
Lichtenstein DL; Craigo JK; Leroux C; Rushlow KE; Cook RF; Cook SJ; Issel CJ; Montelaro RC
Virology; 1999 Oct; 263(2):408-17. PubMed ID: 10544113
[TBL] [Abstract][Full Text] [Related]
7. C-terminal truncation of the transmembrane protein of an attenuated lentiviral vaccine alters its in vitro but not in vivo replication and weakens its potential pathogenicity.
Jiang CG; Gao X; Ma J; Lin YZ; Wang XF; Zhao LP; Hua YP; Liu D; Zhou JH
Virus Res; 2011 Jun; 158(1-2):235-45. PubMed ID: 21539871
[TBL] [Abstract][Full Text] [Related]
8. Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence.
Shen T; Liang H; Tong X; Fan X; He X; Ma Y; Xiang W; Shen R; Zhang X; Shao Y
Vaccine; 2006 Feb; 24(6):738-49. PubMed ID: 16202485
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus.
Hammond SA; Raabe ML; Issel CJ; Montelaro RC
Virology; 1999 Sep; 262(2):416-30. PubMed ID: 10502520
[TBL] [Abstract][Full Text] [Related]
10. Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us?
Leroux C; Cadoré JL; Montelaro RC
Vet Res; 2004; 35(4):485-512. PubMed ID: 15236678
[TBL] [Abstract][Full Text] [Related]
11. An attenuated EIAV vaccine strain induces significantly different immune responses from its pathogenic parental strain although with similar in vivo replication pattern.
Lin YZ; Shen RX; Zhu ZY; Deng XL; Cao XZ; Wang XF; Ma J; Jiang CG; Zhao LP; Lv XL; Shao YM; Zhou JH
Antiviral Res; 2011 Nov; 92(2):292-304. PubMed ID: 21893100
[TBL] [Abstract][Full Text] [Related]
12. Reverse mutation of the virulence-associated S2 gene does not cause an attenuated equine infectious anemia virus strain to revert to pathogenicity.
Gao X; Jiang CG; Wang XF; Lin YZ; Ma J; Han XE; Zhao LP; Shen RX; Xiang WH; Zhou JH
Virology; 2013 Sep; 443(2):321-8. PubMed ID: 23763769
[TBL] [Abstract][Full Text] [Related]
13. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus.
Raabe ML; Issel CJ; Montelaro RC
Virology; 1999 Jul; 259(2):416-27. PubMed ID: 10388665
[TBL] [Abstract][Full Text] [Related]
14. A proviral derivative from a reference attenuated EIAV vaccine strain failed to elicit protective immunity.
Ma J; Shi N; Jiang CG; Lin YZ; Wang XF; Wang S; Lv XL; Zhao LP; Shao YM; Kong XG; Zhou JH; Shen RX
Virology; 2011 Feb; 410(1):96-106. PubMed ID: 21094511
[TBL] [Abstract][Full Text] [Related]
15. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.
Craigo JK; Li F; Steckbeck JD; Durkin S; Howe L; Cook SJ; Issel C; Montelaro RC
J Virol; 2005 Mar; 79(5):2666-77. PubMed ID: 15708986
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the equine infectious anemia virus long terminal repeat during the alteration of cell tropism.
Maury W; Thompson RJ; Jones Q; Bradley S; Denke T; Baccam P; Smazik M; Oaks JL
J Virol; 2005 May; 79(9):5653-64. PubMed ID: 15827180
[TBL] [Abstract][Full Text] [Related]
17. Genetic immunization with codon-optimized equine infectious anemia virus (EIAV) surface unit (SU) envelope protein gene sequences stimulates immune responses in ponies.
Cook RF; Cook SJ; Bolin PS; Howe LJ; Zhou W; Montelaro RC; Issel CJ
Vet Microbiol; 2005 Jun; 108(1-2):23-37. PubMed ID: 15885929
[TBL] [Abstract][Full Text] [Related]
18. Influence of long terminal repeat and env on the virulence phenotype of equine infectious anemia virus.
Payne SL; Pei XF; Jia B; Fagerness A; Fuller FJ
J Virol; 2004 Mar; 78(5):2478-85. PubMed ID: 14963146
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus.
Cook RF; Leroux C; Cook SJ; Berger SL; Lichtenstein DL; Ghabrial NN; Montelaro RC; Issel CJ
J Virol; 1998 Feb; 72(2):1383-93. PubMed ID: 9445039
[TBL] [Abstract][Full Text] [Related]
20. [Expression and immunogenicity of equine infectious anemia virus membrane protein GP90].
Dai CB; Xiao Y; Lu H; Shen RX; Shao YM
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Mar; 17(1):73-6. PubMed ID: 12870025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
